Mycophenolic Acid Monotherapy in Recipients of HLA-identical Living-Related Transplantation

This randomized trial will enroll adult recipients of HLA-identical living kidney
transplants who are at least 1 year post-transplant. All subjects will be taking Prograf
(tacrolimus) or cyclosporine and mycophenolic acid (CellCept or Myfortic) and then be
randomized (1:2) to either continue calcineurin inhibitors or to taper off of calcineurin
inhibitors. The hypothesis is that mycophenolic acid monotherapy permits long-term
rejection-free renal allograft function in the absence of long-term calcineurin inhibitors
in this fully matched renal transplant cohort.